CClinicalTrials.gg
Not yet recruitingNCT07714291Updated Jul 21, 2026

CPHARM - CRC Study

An interventional study of Health awareness campaign in Colorectal Cancer, sponsored by Monash University Malaysia. Not yet recruiting at 1 site in Malaysia. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Monash University Malaysia · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
316
Allocation
Non-randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.

Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.

02

Conditions studied

  • Colorectal Cancer
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 316 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Monash University Malaysia is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults aged 50 to 75 years
  • Visiting participating community pharmacies during the study period
  • Able to provide informed consent
  • Willing to complete the study questionnaire
  • Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of colorectal cancer
  • History of colonoscopy within the recommended screening interval (within past 1 year)
  • Currently experiencing symptoms suggestive of colorectal cancer
  • Having a first-degree relative diagnosed with colorectal cancer
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    Pharmacy customers with campaign

    Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake. The campaign consists of educational materials and one-on-one education about colorectal cancer.

    Behavioral: Health awareness campaign

  • No intervention
    Pharmacy customers without campaign

    Customers will receive standard pharmacy services such as medication dispensing and general health advice, but no educational materials or one-on-one education on CRC will be provided.

Interventions

  • BehavioralHealth awareness campaign

    Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake. The campaign consists of educational materials and one-on-one education about colorectal cancer.

06

What researchers measure

Primary outcomes

  1. Beliefs and perceptions toward colorectal cancer and iFOBT screening

    Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers.

    Time frame: From enrollment to the 8th week follow-up.

Secondary outcomes

  1. Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.

    Time frame: From enrollment to the 8th week of follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714291
Lead sponsor
Monash University Malaysia
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Yen Jun Wong
Contact
yenjun.wong@monash.edu
60355146286
Chee Tao Chang
Contact
davidcct.crc@gmail.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion